The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued for luspate...

Full description

Bibliographic Details
Main Authors: Julio Delgado, Caroline Voltz, Milena Stain, Ewa Balkowiec-Iskra, Brigitte Mueller, Johanna Wernsperger, Iwona Malinowska, Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000616

Internet

http://journals.lww.com/10.1097/HS9.0000000000000616

Similar Items